
New CAR T approach minimises resistance, helps avoid relapse in non-Hodgkin’s B-cell lymphoma
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led…
Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led…
A combination of copanlisib and rituximab led to a 48 percent reduction in the risk…
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to…
Mantle cell lymphoma is a malignant disease in which intensive treatment can prolong life. In…
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer of lymphocytes, and a large proportion…
White blood cells or lymphocytes are the soldiers of our immune system that patrol the…
Monoclonal antibodies are part of the therapeutic arsenal for eliminating cancer cells. Some make use…
Bleomycin is a drug used to treat certain cancers, such as Hodgkin lymphoma and germ…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine (USA) initiated clinical…
In people with central nervous system () lymphoma, cancerous B cells accumulate to form tumours…